It was reported that reduced miR-146a expression in chromosome 5q deletion high-risk (HR) MDS (HR MDS)/AML patients and miR-146a-/- hematopoietic stem/progenitor cells (HSPCs) resulted in TRAF6/NF-kB activation. Here, TRAF6 is linked to myelodysplastic syndrome.